OR WAIT 15 SECS
CordenPharma has announced the expansion of its non-GMP SPPS manufacturing capacity at its Centre of Excellence for Peptide Process Development and non-GMP manufacturing in Frankfurt, Germany.
CordenPharma has announced the expansion of its non-GMP (good manufacturing practice) solid-phase peptide synthesis (SPPS) manufacturing capacity at its Centre of Excellence for Peptide Process Development and non-GMP manufacturing in Frankfurt, Germany.
According to a Nov. 17, 2020 press release, the expansion of the non-GMP SPPS manufacturing capacity will include an increase in available lab space by 25% and the addition of a dedicated explosion proof area. The increased capacity will allow the company to accommodate recent growth in European domestic demand for non-GMP peptide development.
“With the addition of these fully automated larger lines in Frankfurt, assembly, capacity, and flexibility will be significantly increased, reinforcing our leading position in Europe while keeping a flexible and cost-effective approach,” said Dr. Matthieu Giraud, global director of CordenPharma’s Peptides, Lipids and Carbohydrates Platform, in the press release. “Special efforts will be focused on mirroring the new equipment design with that of current GMP in order to ensure smooth technical transfer when it comes to later-stage clinical support. The expanded peptide manufacturing, explosion proof area and tank farm will be available starting Q3 2021.”